sameAs
P3781
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerCombination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice.Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinomaZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brainDouble-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.Role of vandetanib in the management of medullary thyroid cancerZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activityCutaneous pigmentation after photosensitivity induced by vandetanib therapyNew antiangiogenetic agents and non-small cell lung cancer.ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein.Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinomaAbrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells.DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study.Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.Vandetanib for the treatment of thyroid cancer.Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.Vandetanib for the treatment of lung cancer.A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.Vandetanib: a guide to its use in advanced medullary thyroid cancer.Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice.Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms.Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.Effects of respiratory mechanical forces on the pharmacological response of lung cancer cells to chemotherapeutic agents.Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase.ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Vandetanib
@sh
Vandetanib
@sr
vandetanib
@en
vandetanib
@nn
バンデタニブ
@ja
範得他尼
@zh-hant
范得他尼
@zh
范得他尼
@zh-cn
范得他尼
@zh-hans
type
label
Vandetanib
@sh
Vandetanib
@sr
vandetanib
@en
vandetanib
@nn
バンデタニブ
@ja
範得他尼
@zh-hant
范得他尼
@zh
范得他尼
@zh-cn
范得他尼
@zh-hans
altLabel
4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline
@en
CH 331
@en
Caprelsa®
@en
N-(4-Bromo-2-fluorophenyl)-6-m ...... nyl)methoxy)-4-quinazolinamine
@en
N-(4-Bromo-2-fluorophenyl)-6-m ...... -yl)methoxy)quinazolin-4-amine
@en
Vandetanib
@en
ZD 6474
@en
ZD-6474
@en
ZD6474
@en
prefLabel
Vandetanib
@sh
Vandetanib
@sr
vandetanib
@en
vandetanib
@nn
バンデタニブ
@ja
範得他尼
@zh-hant
范得他尼
@zh
范得他尼
@zh-cn
范得他尼
@zh-hans